ERBB2 and breast carcinoma: In summary, our results showed a novel therapeutic strategy by co-targeting BET bromodomain BRD4 and RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, TNBC and HER-2 positive breast cancer.